Categories
Connect with us on LinkedIn
On-site ePRO in Action: A Recap of Castor’s Product Spotlight
Castor’s on-site ePRO adds in-clinic PRO capture to the ePRO/CDMS workflow you already use. Staff use a site...
ICH GCP E6(R3) Implementation: Practical Approaches and Real-World Considerations
ICH GCP E6(R3) implementation requires strategic planning beyond basic compliance. This practical guide covers realistic 12-18 month timelines,...
Decentralized Clinical Trial Platforms in 2025: A Practical Guide for Clinical Operations
DCT platform evaluation guide: integration strategies, vendor comparison, implementation timelines for clinical operations teams.
On-site ePRO
Castor’s On-site ePRO ensures higher flexibility for both study designers and participants, by maximizing opportunities for data capture.
Castor On-site ePRO
Download our On-site ePRO factsheet to view an overview of our services.
EQ-5D in European Trials: When Generic QoL Measures Actually Matter
Analysis of 735 FDA drug approvals reveals 0% EQ-5D labeling inclusion, while European HTA bodies demonstrate 18% technology...
Castor Product Spotlight: New On-site ePRO
Watch this on-demand Product Spotlight to see Castor’s On-site ePRO in action. Our experts show how on-site capture...
Navigating the eCOA Vendor Landscape: What Clinical Teams Really Need to Know
The eCOA market reached $2.27 billion in 2025 with 16.1% projected growth, yet vendor selection remains critical for...
Optimizing eCOA in Oncology Trials: Patient-Focused Data Capture for Cancer Research
Oncology leads clinical innovation with 7,747 trials registered through 2022, yet only 7% of cancer patients participate. This...
ePRO, eCOA 101: Everything You Need to Know About ePRO and eCOA
Electronic Clinical Outcome Assessment (ECOA) and electronic Patient Reported Outcomes (ePRO) represent far more than digital surveys in...
Why eCOA Still Fails in Clinical Trials: Practical Strategies to Fix Baseline Data Problems
Electronic clinical outcome assessments (eCOA) were supposed to solve data quality and amplify the patient voice. Yet missing...
How a 3-Person Team Got to Phase 3 — Without the Overhead
Gameto proves you don’t need a large CRO or a floor of data managers to run complex global...
From Hype to Health: What Sword Health Got Right About Evidence
Sword Health didn’t follow the typical digital health playbook. Instead of rushing to market, they invested early in...
Broken at Baseline: Why eCOA Fails in the Real World (and Why We Don’t Talk About It)
Why are baseline PROs still going uncaptured in 2025? Join Ari Gnanasakthy, Katja Rudell & Derk Arts to...
Castor Bolsters Remote Study Engagement with Streamlined Participant Workflow
OTP login is now standard in Castor’s eConsent platform. No account setup or passwords to create. Participants receive...
The New Standard in Participant-Centric Trials: What Castor’s 2025 Updates Reveal About the Future of Clinical Research
Explore how Castor’s 2025 updates reduce site burden and boost compliance through scalable, flexible DTP workflows.
Building Biotech: From Science to Scale – Strategic Lessons from the Frontline
Hard truths on scaling biotech: data isn’t enough, CEOs matter, and funding follows story—not science.
From Hype to Health: How Sword Built Evidence That Scales
How Sword Health used long-term clinical validation to scale, prove outcomes, and build real credibility in digital MSK...
Connect with us on LinkedIn
